Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

August 10, 2012 10:00 ET

Trimel to Present at Canaccord Genuity 32nd Annual Growth Conference

TORONTO, ONTARIO--(Marketwire - Aug. 10, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) (the "Company" or "Trimel") today announced that it will participate in the Canaccord Genuity 32nd Annual Growth Conference at the InterContinental Hotel in Boston, Massachusetts. Mr Kenneth Howling, Chief Financial Officer, is scheduled to present an overview of the Company on August 14, 2012 at 11:00 am EDT. The presentation materials will also be available on the Trimel website at www.trimelpharmaceuticals.com.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

Contact Information